Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.

@article{Wachtell2007RegressionOE,
  title={Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.},
  author={Kristian Wachtell and Peter M. Okin and Michael H. Olsen and Bj{\"o}rn Dahl{\"o}f and Richard Blyton Devereux and Hans Henning Windel\ov Ibsen and Sverre Erik Kjeldsen and Lars Lindholm and Markku S Nieminen and Kristian Thygesen},
  journal={Circulation},
  year={2007},
  volume={116 7},
  pages={700-5}
}
BACKGROUND Sudden cardiac death (SCD) occurs more often in patients with ECG left ventricular (LV) hypertrophy. However, whether LV hypertrophy regression is associated with a reduced risk of SCD remains unclear. METHODS AND RESULTS The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women]). QRS duration>2440… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 90 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Asso - ciation of left ventricular hypertrophy regression and heart rate reduction with determinants of myocardial oxygen consumption and cardiovascular events : the LIFE study

  • RB Devereux, K Wachtell, +8 authors S Julius
  • J Am Coll Cardiol
  • 2003

Similar Papers

Loading similar papers…